Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24199712.
- Also identified by DOI 10.1016/j.eururo.2013.10.016 and PMC identifier 4676267.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intravesical therapy with bacillus Calmette-Guérin has proven effects for reducing recurrence, progression, and death from non-muscle-invasive bladder cancer. These advantages are seen mainly when appropriate maintenance therapy is used for 1-3 years, in the context of appropriate patient selection, tumor management, and symptom support for potential side effects.
Medical subject headings
- Antineoplastic Agents
- BCG Vaccine
- Urinary Bladder Neoplasms